Interleukin 8 and tumor necrosis factor-α level in acute rheumatic fever and chronic rheumatic heart disease
DOI:
https://doi.org/10.54361/ljmr.v8i1.07Abstract
Forty children were included in this study with age ranging between 5 - 15 years. They were divided into four groups according to clinical presentation. Group I with acute rheumatic arthritis, group II with chorea, group III with clinical carditis and group IV with chronic heart disease. Twenty healthy children were investigated for IL-8 and TNF-α as a control group. We found that the serum level of IL-8 was significantly higher than the control group and in carditis than arthritis. TNF-α was significantly higher in acute rheumatic fever than control group. The result showed that the level of IL-8 and TNF-α were significantly higher in patients with chorea than arthritis. These parameters also were significantly higher in rheumatic chorea than chronic rheumatic heart disease. The recurrence of rheumatic activity and development of chronic rheumatic heart disease was high in patients with high levels of interleukins in acute phase.
Downloads
References
Robinson JH and Kehoe MA. Group A streptococcal M. protein: virulence factors and protective antigens. Immunol Today. 1992, 13: 362-367.
Nordet P. WHO/95FC. Global program for prevention and control of RF/RHD J Int Suc Fed Cardiol. 1993, 3: 4-5.
Eisenberg MJ. Rheumatic heart disease in developing world. Eur Heart J. 1993, 14: 122-128.
Gibofsky A and Zabriskie JB. Rheumatic fever and poststreptococcal reactive arthritis. Curr Opin Rheumatic. 1995, 7; 4: 299-305.
Samsonov MI, Tilz GP, Piskalakove VP and Wadrter H. Serum soluble receptors for TNF-α, IL-2, and neoptrin in rheumatic fever. Clin Immunol Immunopathol. 1995, 74; 1: 31-34.
Wotanabe OR, Aclon J and Tomai MA. Characterization of unique human TCR, BB specificities for a family of streptococcal superantigen, represented by rheumatogenic serotype of M-protein. J Immunol. 1994, 152: 2066-2073.
Narin N, KutuKculer N, Bakiler AR and Parlar A. Lymphocyte subset and IL-1, IL-2, and TNF-α concentration in acute rheumatic fever and chronic heart disease. Clin Immunopathol. 1995, 77; 2: 172-176.
Baggiolini M. J Clin Invest. 1989, 84: 1045-1049.
Eichbaum, QG, Hugher EJ, Epsttein SE and Beatty DW. Rheumatic fever autoantibodies against a variety of cardiac, nuclear and streptococcal antigens. Ann Rheum Dis. 1995, 54; 9: 746.
Morris K, Mohan C and Gangaly NK. Enhancement of IL-1, IL-2, production and IL-2 receptor generation in patients with acute rheumatic fever and active rheumatic heart disease, a prospective study. Clin Exp Immunol. 1993, 91; 3: 429-436.
Kuter Kcuer N. Plasma interleukins in acute rheumatic fever and chronic rheumatic heart disease Scand J Rheumatol. 1995, 24; 6: 383-385.
Downloads
Published
Issue
Section
License
Copyright (c) 2014 Wafa Benzabya (Author)
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Open Access Policy
Libyan journal of medical Research (LJMR).is an open journal, therefore there are no fees required for downloading any publication from the journal website by authors, readers, and institution.
The journal applies the license of CC BY (a Creative Commons Attribution 4.0 International license). This license allows authors to keep ownership f the copyright of their papers. But this license permits any user to download , print out, extract, reuse, archive, and distribute the article, so long as appropriate credit is given to the authors and the source of the work.
The license ensures that the article will be available as widely as possible and that the article can be included in any scientific archive.
Editorial Policy
The publication of an article in a peer reviewed journal is an essential model for Libyan journal of medical Research (LJMR). It is necessary to agree upon standards of expected ethical behavior for all parties involved in the act of publishing: the author, the journal editorial, the peer reviewer and the publisher.
Any manuscript or substantial parts of it, submitted to the journal must not be under consideration by any other journal. In general, the manuscript should not have already been published in any journal or other citable form, although it may have been deposited on a preprint server. Authors are required to ensure that no material submitted as part of a manuscript infringes existing copyrights, or the rights of a third party.
Authorship Policy
The manuscript authorship should be limited to those who have made a significant contribution and intellectual input to the research submitted to the journal, including design, performance, interpretation of the reported study, and writing the manuscript. All those who have made significant contributions should be listed as co-authors.
Others who have participated in certain substantive aspects of the manuscript but without intellectual input should only be recognized in the acknowledgements section of the manuscript. Also, one of the authors should be selected as the corresponding author to communicate with the journal and approve the final version of the manuscript for publication in the LJMR.
Peer-review Policy
- All the manuscripts submitted to LJMR will be subjected to the double-blinded peer-review process;
- The manuscript will be reviewed by two suitable experts in the respective subject area.
- Reports of all the reviewers will be considered while deciding on acceptance/revision or rejection of a manuscript.
- Editor-In-Chief will make the final decision, based on the reviewer’s comments.
- Editor-In-Chief can ask one or more advisory board members for their suggestions upon a manuscript, before making the final decision.
- Associate editor and review editors provide administrative support to maintain the integrity of the peer-review process.
- In case, authors challenge the editor’s negative decision with suitable arguments, the manuscript can be sent to one more reviewer and the final decision will be made based upon his recommendations.
